HIV stands for human immuno-deficiency virus. AIDS stands for acquired immune deficiency syndrome.
Leading scientists from esteemed institutions, such as the Population Council and Stellenbosch University (Capetown, South Africa) are partnering with us to develop a cure.
Top clinicians from revered organizations, like Columbia University Medical Center/New York Presbyterian Hospital, the New York Blood Center, and Rockefeller University have teamed up with us to develop a cure.
People from all walks of life are donating their time, from hosting fundraisers and holding conferences to providing pro bono advertising and marketing.
Chromocell Corporation, a life sciences and technology company, has given the RFTCA complete access to proprietary, cutting-edge technology called Chromovert®. This technology can create curative stem cells that are essential in developing a cure.
Musicians, painters, and artists from other creative areas are lending their talents to help with awareness efforts.
KAMBIZ SHEKDAR, PH.D
Kambiz Shekdar is president and founder of the Research Foundation to Cure AIDS. Prior to establishing the RFTCA, Kambiz served as Chief Scientific Officer of Chromocell Corporation, a biotechnology company he co-founded. He obtained his Ph.D in the laboratory of his mentor, Nobel Laureate Günter Blobel, at Rockefeller University. It was during his graduate studies that Kambiz invented Chromovert® Technology, a novel technology that allows access to highly desired, exceedingly rare cells that had otherwise remained out of reach. This technology was the basis for the Chromocell Corporation, and it holds promise for the development of a cure for AIDS.
PATRICIA MORRIS, PH.D
Dr. Morris serves as an Investigator in the Laboratory of RNA Molecular Biology at Rockefeller University, and as the Executive Director of Biomedical Research and Development and Senior Scientist Emeritus at the Population Council. Trained in pharmacology, endocrinology, and molecular and cell biology, Dr. Morris has been involved in global reproductive health programs and forged alliances with academic, medical, biotech and NGO international organizations. In addition to acting as the long-standing lead investigator and Co-Director of the National Institute of Child Health and Human Development Specialized Centers, Dr. Morris has served as a consultant and senior advisory panel member with expertise in sexual and reproductive health for the National Institutes of Health, Department of Defense, and World Health Organization, among others. She has acted as a principal investigator continuously funded by the NIH since 1983.
ALI HEMMATI-BRIVANLOU, PH.D
Dr. Brivanlou serves as the Robert and Harriet Heilbrunn Professor and is the Head of the Laboratory of Stem Cell Biology and Molecular Embryology at Rockefeller University. He received his doctoral degree in 1990 from the University of California, Berkeley. He joined Rockefeller in 1994 as an assistant professor after completing postdoctoral work in Douglas Melton’s lab at Harvard University. Among his many awards are the Irma T. Hirschl/Monique Weill-Caulier Trusts Career Scientist Award, the Searle Scholar Award, the James A. Shannon Director’s Award from the National Institutes of Health, and the Presidential Early Career Award for Scientists and Engineers. In addition, he serves as Director of the Tri-Institutional Human Embryonic Stem Cell Derivation Unit in New York (Memorial Sloan Kettering, Cornell Medical School, Rockefeller University), and he is the Chair of the Steering Committee for the establishment of the Tri-institutional Stem Cell initiative.
For over 17 years, Allison has committed her creative sensibility and marketing acumen to build brands that help consumers “be better, live better.” As President, Chief Experience Officer at Havas Health Plus, Allison has worked in a range of categories from diabetes, pain, infant nutrition, pharmacy, laundry detergent, and skin care to more serious disease states, such as oncology and MS. Her clients are just as diverse as the products she has worked on, which include blockbuster pharma brands, small tech startups, and national pharmacies. Allison is on the Creative Technology Advisory Board, is an adjunct professor at the Fashion Institute of Technology (FIT), and has worked with the Icahn School of Medicine at Mount Sinai in their advocacy program. Allison has built a strong international background in fine arts at MoMA, NY, and was a fellowship recipient, working at the Peggy Guggenheim Collection in Venice, Italy.
CHARLES KERR, ESQ
Charles Kerr is a former partner at Morrison & Foerster LLP. Mr. Kerr has served as head of the firm’s New York Litigation Practice Group as Managing Partner of the firm’s New York Office and as co-chair of the firm’s Product Liability Group. He is a member of the New York State and American Bar Associations, the New York County Bar Association, and the Association of the Bar of the City of New York. He served as a member of the Association of the Bar of the City of New York’s Standing Committee on Legal Assistance and as a member of the Association of the Bar of the City of New York’s Committee on the Recruitment of Lawyers. Charles Kerr’s practice focuses on complex commercial litigation and regulatory enforcement proceedings. He received his BA from Brown University and his JD from New York University School of Law.
CHRISTIAN KOPFLI, ESQ
Christian co-founded Chromocell in 2002, serving initially as General Counsel before becoming Chief Executive Officer in 2005. Prior to joining Chromocell, he was an Associate at Davis Polk & Wardwell, LLP, working in its New York City, Tokyo, and Frankfurt offices. At Davis Polk, Christian worked extensively in Mergers & Acquisitions, Capital Markets, and Private Equity Transactions. He received a doctoral degree in law (magna cum laude) from the University of Zurich and his LLM from Columbia Law School. Christian is a Board Member of BioNJ and was admitted to the Bar in New York and Switzerland.
KAREN HAGBERG, ESQ
Karen Hagberg is a former partner at Morrison & Foerster, LLP, where she practiced for over 30 years until her retirement earlier this year. She now acts as an independent consultant. Karen’s practice mainly focused on litigation and arbitration of complex commercial cases in the areas of intellectual property and licensing disputes. She advised both domestic and international companies on litigation and protection of intellectual property, including patent, copyright, trademark, and trade secret matters. She served as lead counsel in over a dozen trials and arbitrations in a variety of industries, including electronics: pharmaceutical and life sciences, entertainment, and media. She was a frequent lecturer in locales throughout the U.S. and Asia on legal issues relating to intellectual property rights. She received her B.A. in 1977 from the State University of New York at Binghamton and her J.D. from Cornell Law School.
JESSE ROBERT LOVEJOY, ESQ
Jesse Robert Lovejoy is a Partner and Chief Administrative Officer of Deimos Asset Management LLC. Deimos is a privately held asset management company operating a multi-manager, multi-strategy hedge fund. Prior to that, he served on the Board Orient-Express Hotels Ltd, where he was Chairman of the Board and also Interim CEO at various times. Prior to that, he served previously as Partner, Chief Administrative Officer, and General Counsel of Coatue Management, LLC, Managing Director of Groton Partners LLC, Senior Managing Director of Ripplewood Holdings and as Managing Director and Co‑Head of General Banking at Lazard Frères in New York. He started as an Associate and later as a Partner at Davis Polk & Wardwell. He received his BA From Yale University and his JD cum laude from Columbia Law School, where he was Managing Editor of the Columbia Law Review.
The Research Foundation to Cure AIDS (“RFTCA”) is a not-for-profit corporation exempt from taxation under Section 501(c)(3) ofthe Internal Revenue Code. Donations to RFTCA are tax-deductible to the fullest extent allowable by law. RFTCA has ultimateauthority to use contributions made to it in its discretion for purposes consistent with its tax exempt purpose.
We won’t stop until we find
a cure for AIDS.